Won the “Most Valuable Pharmaceutical Listing Company” from Golden Hong Kong Listed Companies for three consecutive years
2022-07-08

Won the “Most Valuable Pharmaceutical Listing Company” from Golden Hong Kong Listed Companies for three consecutive years

Selected as “Most Attractive Hong Kong Stock-Connect Companies for Institutional Investors”

Selected as “Most Attractive Hong Kong Stock-Connect Companies for Institutional Investors”

Recognized as the “Honored Company” by the Institutional Investors Magazine

Recognized as the “Honored Company” by the Institutional Investors Magazine

Won the “Hong Kong Stock-Connect Company with the Most Substantial Growth Potential” award in Golden Wing Award held by Securities Times

Won the “Hong Kong Stock-Connect Company with the Most Substantial Growth Potential” award in Golden Wing Award held by Securities Times

Awarded the “Shenzhen’s Most Potential Employer”

Awarded the “Shenzhen’s Most Potential Employer”

Invested in four overseas biotech companies including Neurelis, Acticor Biotech, Blueberry Therapeutics and VAXIMM, and acquired assets or product rights of four innovative products including Diazepam Nasal Spray, ACT017 (anti-platelet humanized monoclonal antibody), BB2603 (terbinafine-nano spray) and VXM01 (oral T-cell immune agonist) in Mainland China and/or other countries or regions

Invested in four overseas biotech companies including Neurelis, Acticor Biotech, Blueberry Therapeutics and VAXIMM, and acquired assets or product rights of four innovative products including Diazepam Nasal Spray, ACT017 (anti-platelet humanized monoclonal antibody), BB2603 (terbinafine-nano spray) and VXM01 (oral T-cell immune agonist) in Mainland China and/or other countries or regions

Acquired product rights of two innovative products including novel lead small molecule compounds CF101 and CF102 in Mainland China and/or other countries or regions

Acquired product rights of two innovative products including novel lead small molecule compounds CF101 and CF102 in Mainland China and/or other countries or regions

Acquired assets of PoNS (portable neuromodulation stimulator) in Mainland China and/or other countries or regions

Acquired assets of PoNS (portable neuromodulation stimulator) in Mainland China and/or other countries or regions